Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | July 29, 2016 | July 29, 2016 |
| AbbVie Inc.ABBV · Entity 2800 | Director | May 08, 2026 | May 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date July 29, 2016 · Filed July 29, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 395,819 |
Ending reported balance
After 2016-07-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-07-29 · Exercise / conversion · Acquired 56,000 · Balance 438,682 Row 2 · 2016-07-29 · Tax withholding · Disposed 42,863 · Balance 395,819 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.25 · Expires 2017-02-15 | Direct | 0 |
Reported balance
After 2016-07-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2016-07-29 · Exercise / conversion · Disposed 56,000 · Balance 0 F6: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 1,130 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,130 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of July 28, 2016. |
| Common shares without par valueSEC Table I · non-derivative | IndirectAnnette Newton-Freyman 1994 Trust | 4,000 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 4,000 F2: Held in the Annette Newton-Freyman 1994 Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities. |
| Common shares without par valueSEC Table I · non-derivative | IndirectAnnette Newton-Freyman 2012 Irrevocable Trust | 76,000 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 76,000 F3: Held in the Annette Newton-Freyman 2012 Irrevocable Trust. The reporting person is trustee of the trust. The trust is irrevocable. The reporting person disclaims beneficial ownership of these securities. |
| Common shares without par valueSEC Table I · non-derivative | IndirectThomas C. Freyman 2012 Irrevocable Trust | 76,000 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 76,000 F4: Held in the Thomas C. Freyman 2012 Irrevocable Trust. The reporting person's spouse is trustee of the trust. The trust is irrevocable. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy spouse as trustee for son | 1,941 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 1,941 F5: These shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy spouse as trustee for son | 1,941 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 1,941 F5: These shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of July 28, 2016.
F2: Held in the Annette Newton-Freyman 1994 Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities.
F3: Held in the Annette Newton-Freyman 2012 Irrevocable Trust. The reporting person is trustee of the trust. The trust is irrevocable. The reporting person disclaims beneficial ownership of these securities.
F4: Held in the Thomas C. Freyman 2012 Irrevocable Trust. The reporting person's spouse is trustee of the trust. The trust is irrevocable.
F5: These shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities.
F6: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
AbbVie Inc.
Report date May 08, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 127,869 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Grant · Acquired 1,118 · Balance 127,869 F1: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse in trust | 4,000 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,000 F2: The reporting person's spouse is the trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse in trust for son | 1,941 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,941 F3: Shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse in trust for son | 1,941 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,941 F3: Shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2: The reporting person's spouse is the trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities.
F3: Shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Allergan plc
Report date May 08, 2020 · Filed May 12, 2020
Section 16 reporting ended · disclosed 2020-05-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-08 · Disposition to issuer · Disposed 2,983 · Balance 0 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
HANGER, INC.
Report date October 03, 2022 · Filed October 04, 2022
Section 16 reporting ended · disclosed 2022-10-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 43,561 · Balance 0 F1: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash.
TENNECO INC
Report date November 17, 2022 · Filed November 21, 2022
Section 16 reporting ended · disclosed 2022-11-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-17 transaction · row 1
1 source rowRow 1 · 2022-11-17 · Disposition to issuer · Disposed 93,892 · Balance 0 F1: Reflects disposition upon completion of the merger (the "Merger") of Pegasus Merger Co. ("Merger Sub"), a wholly owned subsidiary of Pegasus Holdings III, LLC ("Parent"), with and into the Issuer, effective November 17, 2022. Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2022, by and among the Issuer, Parent and Merger Sub, upon completion of the Merger, each outstanding share of the Issuer's Class A Common Stock was converted into the right to receive $20.00 per share in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition upon completion of the merger (the "Merger") of Pegasus Merger Co. ("Merger Sub"), a wholly owned subsidiary of Pegasus Holdings III, LLC ("Parent"), with and into the Issuer, effective November 17, 2022. Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2022, by and among the Issuer, Parent and Merger Sub, upon completion of the Merger, each outstanding share of the Issuer's Class A Common Stock was converted into the right to receive $20.00 per share in cash.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2007 Filed Jan 5, 2007 19:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 17,406 | $48.71 | $847,846.26 |
DisclosureSEC source: 0001104659-07-000911 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,609 Read SEC document |
| January 03, 2007 Filed Jan 5, 2007 19:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 17,828 | $46.92 | $836,482.63 |
DisclosureSEC source: 0001104659-07-000911 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2006 Filed Jul 27, 2006 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,355 | $0.00 Strike: $42.42 | $0.00 |
DisclosureSEC source: 0001104659-06-049351 · a4.xml · derivative · entry 9 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 2,355 shares Expires 2007-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| July 25, 2006 Filed Jul 27, 2006 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 4,073 | $0.00 Strike: $41.97 | $0.00 |
DisclosureSEC source: 0001104659-06-049351 · a4.xml · derivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 4.073 shares Expires 2007-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| July 25, 2006 Filed Jul 27, 2006 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,984 | $47.56 | $284,599.04 |
DisclosureSEC source: 0001104659-06-049351 · a4.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,187 Read SEC document |
| July 25, 2006 Filed Jul 27, 2006 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,355 | $42.42 | $99,905.22 |
DisclosureSEC source: 0001104659-06-049351 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2006 Filed Jul 27, 2006 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 4,073 | $41.97 | $170,949.92 |
DisclosureSEC source: 0001104659-06-049351 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2006 Filed Mar 2, 2006 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,299 | $43.81 | $188,339.19 |
DisclosureSEC source: 0001104659-06-013600 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,743 Read SEC document |
| February 18, 2006 Filed Feb 22, 2006 22:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,223 | $44.15 | $53,995.45 |
DisclosureSEC source: 0001104659-06-011222 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,442 Read SEC document |
| February 17, 2006 Filed Feb 22, 2006 22:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 83,000 | $0.00 Strike: $44.16 | $0.00 |
DisclosureSEC source: 0001104659-06-011222 · a4.xml · derivative · entry 7 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: common shares · 83,000 shares Expires 2016-02-16 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) Rule 16b-3. The option becomes exercisable in annual increments of 27,667 on 2/17/2007, 27,667 on 2/17/2008 and 27,666 on 2/17/2009. Read SEC document |
| February 17, 2006 Filed Feb 22, 2006 22:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 28,600 | $44.16 | $1,262,976.00 |
DisclosureSEC source: 0001104659-06-011222 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,042 F1 · kind: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2006 Filed Feb 17, 2006 00:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 29,245 | $0.00 Strike: $43.73 | $0.00 |
DisclosureSEC source: 0001104659-06-010254 · a4.xml · derivative · entry 9 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,245 Underlying: common shares · 29,245 shares Expires 2013-02-13 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 15, 2006 Filed Feb 17, 2006 00:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 35,468 | $0.00 Strike: $33.23 | $0.00 |
DisclosureSEC source: 0001104659-06-010254 · a4.xml · derivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 35,468 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 15, 2006 Filed Feb 17, 2006 00:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 780 | $43.85 | $34,203.00 |
DisclosureSEC source: 0001104659-06-010254 · a4.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,665 Read SEC document |
| February 15, 2006 Filed Feb 17, 2006 00:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 29,245 | $43.73 | $1,278,883.85 |
DisclosureSEC source: 0001104659-06-010254 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,445 Read SEC document |
| February 15, 2006 Filed Feb 17, 2006 00:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 35,468 | $33.23 | $1,178,651.30 |
DisclosureSEC source: 0001104659-06-010254 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2006 Filed Feb 1, 2006 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 23,224 | $0.00 Strike: $41.97 | $0.00 |
DisclosureSEC source: 0001104659-06-005427 · a4.xml · derivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 23,224 shares Expires 2006-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 30, 2006 Filed Feb 1, 2006 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 466 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-06-005427 · a4.xml · nonDerivative · entry 6 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By self for son Disclosed balance after: 466 F1 · ownership.direct: Reporting person disclaims beneficial ownership of all securities held by his daughter and sons. Read SEC document |
| January 30, 2006 Filed Feb 1, 2006 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 466 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-06-005427 · a4.xml · nonDerivative · entry 5 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By self for son Disclosed balance after: 466 F1 · ownership.direct: Reporting person disclaims beneficial ownership of all securities held by his daughter and sons. Read SEC document |
| January 30, 2006 Filed Feb 1, 2006 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 466 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-06-005427 · a4.xml · nonDerivative · entry 4 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 466 F1 · ownership.direct: Reporting person disclaims beneficial ownership of all securities held by his daughter and sons. Read SEC document |
| January 30, 2006 Filed Feb 1, 2006 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 1,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-06-005427 · a4.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,222 Read SEC document |
| January 30, 2006 Filed Feb 1, 2006 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 22,867 | $43.00 | $983,281.00 |
DisclosureSEC source: 0001104659-06-005427 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,620 Read SEC document |
| January 30, 2006 Filed Feb 1, 2006 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 23,224 | $41.97 | $974,746.12 |
DisclosureSEC source: 0001104659-06-005427 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2005 Filed Mar 10, 2005 20:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 29,290 | $0.00 Strike: $46.65 | $0.00 |
DisclosureSEC source: 0001104659-05-010375 · a4.xml · derivative · entry 7 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,290 Underlying: common shares · 29,290 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| March 08, 2005 Filed Mar 10, 2005 20:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 35,468 | $0.00 Strike: $33.23 | $0.00 |
DisclosureSEC source: 0001104659-05-010375 · a4.xml · derivative · entry 6 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,468 Underlying: common shares · 35,468 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| March 08, 2005 Filed Mar 10, 2005 20:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 15,894 | $0.00 Strike: $41.97 | $0.00 |
DisclosureSEC source: 0001104659-05-010375 · a4.xml · derivative · entry 5 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 15,894 shares Expires 2005-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| March 08, 2005 Filed Mar 10, 2005 20:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 44,219 | $46.65 | $2,062,816.35 |
DisclosureSEC source: 0001104659-05-010375 · a4.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,263 Read SEC document |
| March 08, 2005 Filed Mar 10, 2005 20:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 35,468 | $33.23 | $1,178,651.30 |
DisclosureSEC source: 0001104659-05-010375 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2005 Filed Mar 10, 2005 20:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 15,894 | $41.97 | $667,095.02 |
DisclosureSEC source: 0001104659-05-010375 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2005 Filed Feb 23, 2005 22:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 63,800 | $0.00 Strike: $46.34 | $0.00 |
DisclosureSEC source: 0001104659-05-008013 · a4.xml · derivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,800 Underlying: common shares · 63,800 shares Expires 2015-02-17 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 21,267 on 2/18/06, 21,267 on 2/18/07 and 21,266 on 2/18/08. Read SEC document |
| February 18, 2005 Filed Feb 23, 2005 22:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 9,300 | $46.34 | $430,962.00 |
DisclosureSEC source: 0001104659-05-008013 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,120 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| November 04, 2004 Filed Nov 8, 2004 19:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 2,292 | $0.00 Strike: $43.61 | $0.00 |
DisclosureSEC source: 0001104659-04-034242 · a4.xml · derivative · entry 5 FREYMAN THOMAS C · CIK 0001239126 · Executive VP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,292 Underlying: common shares · 2,292 shares Expires 2008-02-12 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| November 04, 2004 Filed Nov 8, 2004 19:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,875 | $0.00 Strike: $34.77 | $0.00 |
DisclosureSEC source: 0001104659-04-034242 · a4.xml · derivative · entry 4 FREYMAN THOMAS C · CIK 0001239126 · Executive VP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 2,875 shares Expires 2008-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| November 04, 2004 Filed Nov 8, 2004 19:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,292 | $43.61 | $99,954.12 |
DisclosureSEC source: 0001104659-04-034242 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive VP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,820 Read SEC document |
| November 04, 2004 Filed Nov 8, 2004 19:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,875 | $34.77 | $99,971.51 |
DisclosureSEC source: 0001104659-04-034242 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive VP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005607 · a4.xml · derivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: common shares · 55,000 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 18,334 on 2/20/05, 18,333 on 2/20/06 and 18,333 on 2/20/07. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 8,000 | $43.66 | $349,280.00 |
DisclosureSEC source: 0001104659-04-005607 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,237 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2004 Filed Feb 18, 2004 23:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 29,257 | $0.00 Strike: $44.31 | $0.00 |
DisclosureSEC source: 0001104659-04-005015 · a4.xml · derivative · entry 6 FREYMAN THOMAS C · CIK 0001239126 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,257 Underlying: common shares · 29,257 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 17, 2004 Filed Feb 18, 2004 23:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 33,333 | $0.00 Strike: $35.36 | $0.00 |
DisclosureSEC source: 0001104659-04-005015 · a4.xml · derivative · entry 5 FREYMAN THOMAS C · CIK 0001239126 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,667 Underlying: common shares · 33,333 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2004 Filed Feb 18, 2004 23:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 29,257 | $44.31 | $1,296,377.67 |
DisclosureSEC source: 0001104659-04-005015 · a4.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,237 Read SEC document |
| February 17, 2004 Filed Feb 18, 2004 23:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 33,333 | $35.36 | $1,178,654.88 |
DisclosureSEC source: 0001104659-04-005015 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2004 Filed Feb 18, 2004 23:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 562 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-04-005015 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,161 Read SEC document |
| January 22, 2004 Filed Jan 26, 2004 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 23,199 | $0.00 Strike: $43.70 | $0.00 |
DisclosureSEC source: 0001104659-04-001715 · a4.xml · derivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,199 Underlying: Common shares · 23,199 shares Expires 2010-02-10 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 22, 2004 Filed Jan 26, 2004 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 26,666 | $0.00 Strike: $34.70 | $0.00 |
DisclosureSEC source: 0001104659-04-001715 · a4.xml · derivative · entry 7 FREYMAN THOMAS C · CIK 0001239126 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 26,666 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2004 Filed Jan 26, 2004 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 10,216 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0001104659-04-001715 · a4.xml · derivative · entry 6 FREYMAN THOMAS C · CIK 0001239126 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 10,216 shares Expires 2005-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2004 Filed Jan 26, 2004 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 27,773 | $43.70 | $1,213,680.10 |
DisclosureSEC source: 0001104659-04-001715 · a4.xml · nonDerivative · entry 4 FREYMAN THOMAS C · CIK 0001239126 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,723 Read SEC document |
| January 22, 2004 Filed Jan 26, 2004 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 26,666 | $34.70 | $925,310.20 |
DisclosureSEC source: 0001104659-04-001715 · a4.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2004 Filed Jan 26, 2004 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 10,216 | $19.57 | $199,927.12 |
DisclosureSEC source: 0001104659-04-001715 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2003 Filed Jan 26, 2004 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 480 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-04-001715 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,614 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.